Download PDF
Z Gastroenterol 2012; 50(11): 1171-1175
DOI: 10.1055/s-0032-1312865
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Humanes Beta-Defensin 1: Aus der Defensive gelockt

Human beta-Defensin 1: From Defence to Offence
B. O. Schroeder
1   Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie
,
E. F. Stange
2   Zentrum für Innere Medizin I, Robert-Bosch-Krankenhaus, Stuttgart
,
J. Wehkamp
1   Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie
2   Zentrum für Innere Medizin I, Robert-Bosch-Krankenhaus, Stuttgart
› Author Affiliations
Further Information

Publication History

21 February 2012

04 May 2012

Publication Date:
13 November 2012 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Der Darm eines erwachsenen Menschen enthält etwa ein Kilogramm kommensale Bakterien. Diese Mikroorganismen stellen eine potenzielle Bedrohung dar, sodass ein effizientes Abwehrsystem essenziell zur Verhinderung von bakterieller Translokation und Infektionen ist. Neben anderen Verteidigungsmechanismen produziert der Mensch antimikrobielle Peptide (AMPs) als körpereigene Antibiotika, die in der Lage sind, Mikroorganismen abzutöten. Die wichtigste Gruppe der humanen AMPs sind die Defensine. Unter diesen spielt das humane β-Defensin 1 (hBD-1) eine entscheidende Rolle, denn es wird konstitutiv von allen Epithelien produziert. Allerdings war die biologische Funktion des hBD-1 lange unklar, denn im Gegensatz zu anderen AMPs zeigte es in vitro kaum antibiotische Aktivität. Jedoch sind verschiedene Erkrankungen mit genetischen Polymorphismen im hBD-1-Gen assoziiert. Hier diskutieren wir, warum die wahre Aktivität von hBD-1 bislang übersehen wurde und wie hBD-1 durch chemische Reduktion aktiviert werden kann. Wir erörtern die biologische Bedeutung der Aktivierung und die Bedeutung für chronisch-entzündliche Darmerkrankungen.

Abstract

The human gut is colonised by about one kilogram of commensal bacteria. These microorganisms are a potential threat, thus an efficient defence system is crucial in preventing bacterial translocation and infection. Besides other mechanisms of protection humans produce antimicrobial peptides (AMPs) that are able to kill a broad range of microorganisms. The human beta-defensin 1 (hBD-1) plays a major role because it is produced constitutively by all human epithelia and some immune cells. In contrast to other AMPs, however, the biological function of hBD-1 has remained unclear since the antibiotic activity of hBD-1 in vitro was only marginal. But still, several diseases have been associated with genetic polymorphisms in the hBD-1 encoding gene. Herein we discuss why the biological role of hBD-1 has been overlooked and how hBD-1 can be activated by chemical reduction. We elaborate on the biological significance of this activation and its importance for inflammatory bowel disease.

Schlüsselwörter

Defensin - hBD-1 - kommensale Bakterien - chronisch entzündliche Darmerkrankung

Key words

defensin - hBD-1 - commensal bacteria - chronic inflammatory bowel disease
 

  • Literatur

  • 1 Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107-133
    CrossrefPubMedGoogle Scholar
  • 2 Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-1638
    CrossrefPubMedGoogle Scholar
  • 3 Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484
    Google Scholar
  • 4 Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-124
    CrossrefPubMedGoogle Scholar
  • 5 Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-254
    CrossrefPubMedGoogle Scholar
  • 6 Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011; 9: 279-290
    CrossrefPubMedGoogle Scholar
  • 7 Ley RE, Turnbaugh PJ, Klein S et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023
    CrossrefPubMedGoogle Scholar
  • 8 Larsen N, Vogensen FK, van den Berg FWJ et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 2010; 5: e9085
    CrossrefPubMedGoogle Scholar
  • 9 Frank DN, St Amand AL, Feldman RA et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci. USA 2007; 104: 13780-13785
    CrossrefPubMedGoogle Scholar
  • 10 Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-594
    CrossrefPubMedGoogle Scholar
  • 11 Fraune S, Bosch TCG. Long-term maintenance of species-specific bacterial microbiota in the basal metazoan Hydra. Proc Natl Acad Sci USA 2007; 104: 13146-13151
    CrossrefPubMedGoogle Scholar
  • 12 Louis P, Scott KP, Duncan SH et al. Understanding the effects of diet on bacterial metabolism in the large intestine. J Appl Microbiol 2007; 102: 1197-1208
    CrossrefPubMedGoogle Scholar
  • 13 Vaishnava S, Behrendt CL, Ismail AS et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 2008; 105: 20858-20863
    CrossrefPubMedGoogle Scholar
  • 14 Salzman NH, Hung K, Haribhai D et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11: 76-83
    CrossrefPubMedGoogle Scholar
  • 15 Zasloff M. Antibiotic peptides as mediators of innate immunity. Curr Opin Immunol 1992; 4: 3-7
    CrossrefPubMedGoogle Scholar
  • 16 Lehrer RI, Ganz T. Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 1999; 11: 23-27
    CrossrefPubMedGoogle Scholar
  • 17 Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-720
    CrossrefPubMedGoogle Scholar
  • 18 Harder J, Gläser R, Schröder JM. Human antimicrobial proteins effectors of innate immunity. J Endotoxin Res 2007; 13: 317-338
    CrossrefPubMedGoogle Scholar
  • 19 Lehrer RI, Ganz T, Selsted ME. Defensins: endogenous antibiotic peptides of animal cells. Cell 1991; 64: 229-230
    CrossrefPubMedGoogle Scholar
  • 20 Martin E, Ganz T, Lehrer RI. Defensins and other endogenous peptide antibiotics of vertebrates. J Leukoc Biol 1995; 58: 128-136
    PubMedGoogle Scholar
  • 21 Ericksen B, Wu Z, Lu W et al. Antibacterial activity and specificity of the six human {alpha}-defensins. Antimicrob Agents Chemother 2005; 49: 269-275
    CrossrefPubMedGoogle Scholar
  • 22 Porter EM, Liu L, Oren A et al. Localization of human intestinal defensin 5 in Paneth cell granules. Infect Immun 1997; 65: 2389-2395
    PubMedGoogle Scholar
  • 23 Wehkamp J, Chu H, Shen B et al. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett 2006; 580: 5344-5350
    CrossrefPubMedGoogle Scholar
  • 24 Bensch KW, Raida M, Mägert HJ et al. hBD-1: a novel beta-defensin from human plasma. FEBS Lett 1995; 368: 331-335
    CrossrefPubMedGoogle Scholar
  • 25 Zhao C, Wang I, Lehrer RI. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett 1996; 396: 319-322
    CrossrefPubMedGoogle Scholar
  • 26 Harder J, Bartels J, Christophers E et al. A peptide antibiotic from human skin. Nature 1997; 387: 861
    CrossrefPubMedGoogle Scholar
  • 27 Harder J, Bartels J, Christophers E et al. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-5713
    CrossrefPubMedGoogle Scholar
  • 28 Kraemer BF, Campbell RA, Schwertz H et al. Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog 2011; 7: e1002355
    CrossrefPubMedGoogle Scholar
  • 29 Valore EV, Park CH, Quayle AJ et al. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J Clin Invest 1998; 101: 1633-1642
    CrossrefPubMedGoogle Scholar
  • 30 Voss E, Wehkamp J, Wehkamp K et al. NOD2 / CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 2006; 281: 2005-2011
    PubMedGoogle Scholar
  • 31 Schlee M, Harder J, Köten B et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008; 151: 528-535
    CrossrefPubMedGoogle Scholar
  • 32 Peyrin-Biroulet L, Beisner J, Wang G et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010; 107: 8772-8777
    CrossrefPubMedGoogle Scholar
  • 33 Tollin M, Bergman P, Svenberg T et al. Antimicrobial peptides in the first line defence of human colon mucosa. Peptides 2003; 24: 523-553
    CrossrefPubMedGoogle Scholar
  • 34 Nuding S, Zabel LT, Enders C et al. Antibacterial activity of human defensins on anaerobic intestinal bacterial species: a major role of HBD-3. Microbes Infect 2009; 11: 384-393
    CrossrefPubMedGoogle Scholar
  • 35 Ozturk A, Famili P, Vieira AR. The antimicrobial peptide DEFB1 is associated with caries. J Dent Res 2010; 89: 631-636
    CrossrefPubMedGoogle Scholar
  • 36 Schaefer AS, Richter GM, Nothnagel M et al. A 3’ UTR transition within DEFB1 is associated with chronic and aggressive periodontitis. Genes Immun 2010; 11: 45-54
    CrossrefPubMedGoogle Scholar
  • 37 Kocsis AK, Lakatos PL, Somogyvári F et al. Association of beta-defensin 1 single nucleotide polymorphisms with Crohn’s disease. Scand J Gastroenterol 2008; 43: 299-307
    CrossrefPubMedGoogle Scholar
  • 38 Lehrer RI, Rosenman M, Harwig SS et al. Ultrasensitive assays for endogenous antimicrobial polypeptides. J Immunol Methods 1991; 137: 167-173
    CrossrefPubMedGoogle Scholar
  • 39 Wilson M. Microbial Inhabitants of Humans – Their Ecology and Role in Health and Disease. University College London: Cambridge University Press; 2005
    Google Scholar
  • 40 Schroeder BO, Wu Z, Nuding S et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature 2011; 469: 419-423
    CrossrefPubMedGoogle Scholar
  • 41 Lehrer RI. Immunology: Peptide gets in shape for self-defence. Nature 2011; 469: 309-310
    CrossrefPubMedGoogle Scholar
  • 42 Nagy E. Anaerobic infections: update on treatment considerations. Drugs 2010; 70: 841-858
    CrossrefPubMedGoogle Scholar
  • 43 Holmgren A. Enzymatic reduction-oxidation of protein disulfides by thioredoxin. Meth Enzymol 1984; 107: 295-300
    PubMedGoogle Scholar
  • 44 Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989; 264: 13963-13966
    PubMedGoogle Scholar
  • 45 Rubartelli A, Bajetto A, Allavena G et al. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 1992; 267: 24161-24164
    PubMedGoogle Scholar
  • 46 Sido B, Giese T, Autschbach F et al. Potential role of thioredoxin in immune responses in intestinal lamina propria T lymphocytes. Eur J Immunol 2005; 35: 408-417
    CrossrefPubMedGoogle Scholar
  • 47 Curbo S, Gaudin R, Carlsten M et al. Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides. Biochem Biophys Res Commun 2009; 390: 1272-1277
    CrossrefPubMedGoogle Scholar
  • 48 Magalhaes JG, Tattoli I, Girardin SE. The intestinal epithelial barrier: how to distinguish between the microbial flora and pathogens. Semin Immunol 2007; 19: 106-115
    CrossrefPubMedGoogle Scholar
  • 49 Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008; 8: 411-420
    CrossrefPubMedGoogle Scholar
  • 50 Wehkamp J, Salzman NH, Porter E et al. Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA 2005; 102: 18129-18134
    CrossrefPubMedGoogle Scholar
  • 51 Nuding S, Fellermann K, Wehkamp J et al. Reduced mucosal antimicrobial activity in Crohn’s disease of the colon. Gut 2007; 56: 1240-1247
    CrossrefPubMedGoogle Scholar
  • 52 Wehkamp J, Koslowski M, Wang G et al. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn’s disease. Mucosal Immunol 2008; 1 (Suppl. 01) S67-S74
    CrossrefPubMedGoogle Scholar
  • 53 Perminow G, Beisner J, Koslowski M et al. Defective paneth cell-mediated host defense in pediatric ileal Crohn’s disease. Am J Gastroenterol 2010; 105: 452-459
    CrossrefPubMedGoogle Scholar
  • 54 Tamaki H, Nakamura H, Nishio A et al. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006; 131: 1110-1131
    CrossrefPubMedGoogle Scholar
  • 55 Scudiero O, Galdiero S, Cantisani M et al. Novel synthetic, salt-resistant analogs of human beta-defensins 1 and 3 endowed with enhanced antimicrobial activity. Antimicrob Agents Chemother 2010; 54: 2312-2322
    CrossrefPubMedGoogle Scholar